For the quarter ending 2026-03-31, AUTL has $527,065K in assets. $418,239K in debts. $130,925K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 130,925 | 86,124 | 123,825 | |
| Marketable securities - available-for-sale debt securities | 98,509 | 281,289 | 330,454 | |
| Restricted cash | 1,493 | 1,498 | 1,507 | |
| Accounts receivable, net | - | 32,604 | 26,644 | |
| Accounts receivable | 27,663 | - | - | |
| Inventories, net | 33,233 | 27,723 | 23,943 | |
| Prepaid expenses and other current assets | 77,012 | 85,339 | 67,877 | |
| Total current assets | 368,835 | 514,577 | 574,250 | |
| Property and equipment, net | 61,908 | 66,851 | 66,467 | |
| Intangible assets, net | 18,976 | 20,283 | 12,933 | |
| Prepaid expenses and other non-current assets | 194 | 191 | 5,258 | |
| Operating lease right-of-use assets, net | 72,563 | 56,625 | 58,619 | |
| Long-term deposits | 1,014 | 1,031 | 1,052 | |
| Deferred tax asset | 3,575 | 2,389 | 2,402 | |
| Total assets | 527,065 | 661,947 | 720,981 | |
| Accounts payable | 1,872 | 10,967 | 5,408 | |
| Compensation and benefits | 18,718 | - | - | |
| Manufacturing accruals | 7,544 | - | - | |
| Rebates, chargebacks and returns | 6,730 | - | - | |
| Professional fees | 5,655 | - | - | |
| Research and development costs | 5,506 | - | - | |
| Other liabilities | 2,613 | - | - | |
| Accrued expenses and other liabilities | 46,766 | 52,264 | 51,366 | |
| Deferred revenue | - | 7,612 | 2,100 | |
| Operating lease liabilities, current | 3,061 | 4,828 | 3,277 | |
| Liabilities related to future royalties and milestones, net - current | 11,900 | 7,400 | 6,000 | |
| Total current liabilities | 63,599 | 83,071 | 68,151 | |
| Operating lease liabilities, non-current | 76,895 | 61,007 | 61,258 | |
| Liabilities related to future royalties and milestones, net - non-current | 277,268 | 251,945 | 244,631 | |
| Other long-term payables | 477 | 472 | 477 | |
| Total liabilities | 418,239 | 396,495 | 374,517 | |
| Ordinary and deferred shares, value-Ordinary Shares | 12 | 12 | 12 | |
| Ordinary and deferred shares, value-Deferred Shares | 0 | 0 | 0 | |
| Ordinary and deferred shares, value-Deferred Class BShares | 118 | 118 | 118 | |
| Ordinary and deferred shares, value-Deferred Class CShares | 0 | 0 | 0 | |
| Additional paid-in capital | 1,573,673 | 1,566,662 | 1,562,774 | |
| Accumulated other comprehensive loss | -6,627 | -4,920 | 862 | |
| Accumulated deficit | -1,458,350 | -1,296,420 | -1,217,302 | |
| Total shareholders equity | 108,826 | 265,452 | 346,464 | |
| Total liabilities and shareholders equity | 527,065 | 661,947 | 720,981 | |
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)